Liraglutide
Liraglutide is a pharmaceutical drug with 306 clinical trials. Currently 14 active trials ongoing. Historical success rate of 94.5%.
Success Metrics
Based on 240 completed trials
Phase Distribution
Phase Distribution
57
Early Stage
51
Mid Stage
152
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
92.0%
240 of 261 finished
8.0%
21 ended early
14
trials recruiting
306
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
Liraglutide Effect in Atrial Fibrillation
Saxenda: Underlying Mechanisms and Clinical Outcomes
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Clinical Trials (306)
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
Liraglutide Effect in Atrial Fibrillation
Saxenda: Underlying Mechanisms and Clinical Outcomes
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Effects of GH and Lirglutide on AgRP
Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Anti-obesity Pharmacotherapy and Inflammation
HbA1c Variability in Type II Diabetes
Liraglutide in Adolescents With Type 1 Diabetes
Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
Liraglutide and Peripheral Artery Disease
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 306